Lenabasum fails to meet primary endpoint in phase III trial for systemic sclerosis

In the Phase III RESOLVE-1 trial, this oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 failed to improve the ACR CRISS score at 52 weeks vs placebo.


Biospace Inc.